Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efgartigimod in post-COVID-19 POTS
NCT05918978Phase 2Terminated
- Sponsor
- argenx
- Start
- Jun 2023
- Primary completion
- Aug 2024
- Modality
- Antibody Fragments
- Countries
- 1
01
Overview
A Phase 2 trial of efgartigimod alfa in postural orthostatic tachycardia syndrome (POTS), sponsored by argenx. Started Jun 2023; status: terminated.
02
Drugs
efgartigimod alfa
03
Conditions
postural orthostatic tachycardia syndrome (POTS)
Beyond the preview
Go deeper on NCT05918978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05918978.